KM Research Hub
← 返回论文库
处理中 入排:排除 图源:可得 入排置信度 0.98

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis.

João Sérgio Neves, Ana Rita Leite, Francisco Vasques-Nóvoa, Bertram Pitt, Gerasimos Filippatos, Luis M Ruilope, Peter Rossing, Stefan D Anker, Gianluigi Savarese, Charlie A B Scott, Andrea Lage, Meike D Brinker, João Pedro Ferreira

Diabetes Obes Metab 28(7) 6022-6033

PMID42027097
PMCIDPMC13243951
DOI10.1111/dom.70750
发表日期2026-04-24
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

AIMS: The American Diabetes Association recommends achieving treatment goals (glycated haemoglobin ≤ 53 mmol/mol [7.0%], blood pressure < 130/80 mmHg, low-density lipoprotein cholesterol < 1.81 mmol/L and use of sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists), to reduce cardiovascular and kidney complications in people with chronic kidney disease and type 2 diabetes. This exploratory study assessed whether treatment effects of finerenone versus placebo were modified by the number of treatment goals met at baseline. MATERIALS AND METHODS: FIDELITY, a prespecified pooled analysis, combined participant-level data from the randomized, double-blind, multicentre phase III FIDELIO-DKD (NCT02540993) and FIGARO-DKD (NCT02545049) trials. Participants with type 2 diabetes and chronic kidney disease were randomized 1:1 to finerenone or placebo. Composite cardiovascular and kidney outcomes, hospitalization for heart failure or cardiovascular death, hospitalization for heart failure and treatment-emergent adverse events were assessed by subgroups based on the number of treatment goals achieved. RESULTS: At baseline, 29%, 40%, 24% and 7% of participants had met 0, 1, 2 and ≥ 3 treatment goals, respectively. Those with more treatment goals met had fewer composite cardiovascular outcomes (events per 100 patient-years in the placebo group: 6.0, 5.1, 4.3 and 3.5 for 0, 1, 2 and ≥ 3 treatment goals, respectively). Similar patterns were observed for other outcomes. There was no heterogeneity in the effect of finerenone versus placebo on outcomes between subgroups. The safety profile of finerenone (vs. placebo) was similar across subgroups. CONCLUSIONS: Finerenone demonstrated treatment benefits in people with chronic kidney disease and type 2 diabetes, irrespective of treatment goals achieved at baseline.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 CV and kidney outcome event rate according to the number of treatment goals met at baseline (placebo arm). CV, cardiovascular; HHF, hospitalization for heart failure.
非 KM Figure
FIGURE 2Cox proportional hazards model for (A) CV and (B) kidney outcomes by the number of treatment goals met at baseline. Data are shown for the full analysis set. Events were adjudicated by an independent adjudication committee and considered from randomization up until the end‐of‐study visit. A stratified Cox proportional hazards model including treatment was calculated separately by subgroup category. The interaction p ‐value was based on a stratified Cox proportional hazards model including treatment, subgroup and treatment by subgroup interaction. Events based on a sustained decrease in eGFR were considered from randomization up until 5 months after the last eGFR was recorded at a clinic visit. a Time to CV death, nonfatal myocardial infarction, nonfatal stroke or HHF. b Time to onset of kidney failure, a sustained ≥ 57% decrease in eGFR from baseline over ≥ 4 weeks, or kidney‐related death. CV, cardiovascular; eGFR, estimated glomerular filtration rate; HHF, hospitalization for heart failure; PY, patient‐years.
非 KM Figure